Newsbenzinga
Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients
· Published
Article summary
Pfizer's sigvotatug vedotin missed its Phase 3 OS goal in NSCLC but showed encouraging results in second-line patients.
An excerpt from the original article.
Comments —
Loading comments…